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Abstract
This chapter reviews various interferon (IFN) system disturbances—inter-
feronopathies. The authors describe clinical specifics of type I interferonopathy 
associated with overexpression of IFNα—which is a rare Mendelian genetic 
disease. Certain autoimmune diseases (systemic lupus erythematosus (SLE), 
vasculitis, immune dysregulation syndrome, etc.) are also characterized by 
overproduction of IFNα. Furthermore the most common interferonopathies are 
described—deficiencies of IFN, congenital or acquired IFNα/IFNβ and IFNγ 
deficiencies in children and adults. Deficiency of IFNα/IFNβ associated with 
severe recurrent viral infections and deficiency of IFNγ cause mycobacterial infec-
tion. Interferon-corrective therapy methods are described. The target therapy of 
type I interferonopathies (biologics) binds IFNα and normalizes the high level of 
IFNα. From the other side, patients with congenital IFNα deficiencies are needed 
in replacement IFN therapy. In case of acquired IFNα deficiency, the differentiated 
interferon-corrective therapy is performed. In both replacement and interferon-
corrective therapies, recombinant human IFNα2b in complex with antioxidants 
(Viferon®) can be used, because their application is safe and has good clinical 
efficiency and no side effects.
Keywords: interferonopathies, interferon deficiency, interferon overexpression, 
IFN-corrective therapy
1. Introduction
Type I interferonopathies are congenital genetic disorder of the interferon 
(IFN) system, characterized by certain clinical symptoms resulting from the 
overproduction of IFNα [1–3]. In our opinion, the term interferonopathy means a 
general pathology of the interferon system, congenital or acquired, which includes 
the following types of disorders of the IFN system: deficiency; paralysis of the IFN 
system; inadequate response on viruses, bacteria, and mutated tumor cells; and 
overproduction of type I IFN. Interferons are the cornerstone of immune defense 
against viral infections and are also involved in the regulation of immune responses. 
Currently there are isolated type I, II, and III interferons in accordance with their 
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ability to interact with the three types of receptors. Type I interferons include IFNα/
IFNβ; type II interferons, IFNγ; and type III interferons, interferon-like cytokines 
(IL-29, IL-28A, IL-28B) [4].
2. Molecular mechanisms of the induction of type I interferon synthesis
The main role of type I interferons is to control viral infection. The synthesis 
and secretion of type I IFN is activated when our immune cells come in contact 
with viruses. Type I IFN is synthesized by epithelial cells, many cells of the immune 
system, including plasmacytoid dendritic cells (pDC) that recognize foreign or auto 
nucleic acids. Although both epithelial and pDC synthesize type I IFN simultane-
ously in different tissues, pDC-derived type I IFN actually exerts various immune 
responses through its cognate receptors on target cells. This results in modulation of 
diverse processes such as antigen presentation and activation of adaptive immunolog-
ical process involving B and T cells [5]. For the synthesis of interferons in the body, 
cell activation is necessary. Toll-like receptors (TLRs); RIG-like receptors (RLRs), 
RIG-I; melanoma differentiation-associated protein 5 (MDA5); and cyclic GMP-AMP 
synthase (cGAS) participate in the recognition of foreign and host nucleic acid sites 
[6]. The main inducers of the synthesis of type I interferons are double-stranded 
and single-stranded RNA of viruses, as well as bacterial DNA [7]. RIG-like recep-
tors recognize both single- and double-stranded viral RNAs, whereas cGAS (cyclic 
GMP-AMP synthase), in contrast, recognizes double-stranded DNA and RNA: DNA 
duplexes are formed during the replication of retroviruses and catalyze the synthesis 
of cGMP-AMP, which is the main agonist of the adapter protein—STING. After 
binding RNA, RIG-I and MDA5 bind the mitochondrial antiviral-signaling (MAVS) 
adapter protein. Both STING and MAVS stimulate downstream signaling cascades 
that include multiple kinases and finally lead to phosphorylation of IRF3 and induc-
tion of interferon synthesis [8]. Then type I IFN binds to the corresponding IFNAR 
Figure 1. 
Molecular mechanisms of the induction of type I and III interferon synthesis. PAMPs: dsRNA, double-
stranded RNA; ssRNA, single-stranded RNA. Nucleic acid sensors: cGAS, cyclic GMP-AMP synthase; MDA5, 
melanoma differentiation-associated protein 5; RIG-I, RIG-I-like receptor dsRNA helicase enzyme. Adaptor 
proteins: TIRAP, toll-interleukin 1 receptor (TIR) domain-containing adaptor protein; MAVS, mitochondrial 
antiviral-signaling protein; STAT, signal transducer and activator of transcription. Nuclear factors: IRF, IFN 
regulatory factor; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells; IFNAR, IFNα 
receptor; ISGs, interferon-stimulated genes; Tyk, tyrosine kinase; Jak, Janus kinase.
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receptors located on the cell membrane, which leads to the activation of Tyk2 and 
Jak1 kinases, which undergo phosphorylation and activate signal transduction and 
transcription activation proteins (STAT1 and STAT2). As a result, a heterotrimeric 
complex is formed, known as IFN-stimulating gene factor-3 (ISGF3), which includes 
IFN regulatory factor 9 (IRF9). Janus kinase (Jak) activation is negatively regulated 
by IFNα-inducible proteins SOCS1 and SOCS3. The binding of ISGF3 promotes 
interferon-stimulated genes (ISGs), which leads to their transcriptional activation 
and the collective actions of hundreds of ISGs, resulting in the production of a 
large number of induced IFN, which inhibits both viral replication and the spread 
of viruses. Rapid type I IFN secretion and then rapid synthesis induce activity of 
congenital and adaptive immunity cells by activation of pro-inflammatory cytokines 
that activate cellular and humoral antiviral immune response [9] (Figure 1).
3. Interferonopathies classification
During acute viral infection, IFN level is significantly elevated, and more than 
70% of cells acquire antiviral status, i.e., they are protected against virus penetration 
and are able to efficiently neutralize them. Type I IFN has several very important posi-
tive effects: direct and indirect antiviral effect, protective antiviral effect, antitumor 
effect, and immunomodulatory effect. At the same time, it was shown that increased 
production of IFN can lead to negative consequences similar to autoimmune reactions.
The information presented by several authors about interferon system patholo-
gies is vast and diverse but is not well-systematized. All known defects of IFN 
system, including type I and II IFN, whether congenital or acquired, including 
various disorders (deficiency; inadequate response to contact with viruses, bac-
teria, and mutated or tumor cells; IFN system paralysis; IFN overexpression), are 
pathologies of IFN system. All those defects of IFN system are collectively known 
as interferonopathies. There is an urgent need to create a classification of congenital 
and acquired disorders of the IFN system. We believe that the classification of IFN 
pathology would help in determining the correct approaches to the differentiated 
choice of adequate treatment tactics.
Based on our own and others’ experience, we have developed the 
interferonopathies classification as per the following table [1–3, 10–15] (Table 1).
3.1 Congenital type I interferonopathies associated with IFNα overexpression
Recently several studies have presented genetic and molecular disorders accom-
panying rare Mendelian diseases that are associated with type I IFN overexpression 
resulting from defects in intracellular nucleic acid metabolism, DNAse deficiency, 
or defects in sensor nucleic acid recognition. Genetic disorders—Mendelian diseases 
(Aicardi-Goutières syndrome, familial chilblain lupus, spondyenchondromatosis, 
proteasome-associated autoinflammatory syndrome, Singleton-Merten syndrome)—
resulting in inadequately high type I IFN overexpression accompanied by a certain 
range of clinical disorders are called type I interferonopathies. Interferonopathies 
have rare pathology; their occurrence varies from 1:10,000 to 1:1,000,000 people. 
According to the literature, the most common syndrome is Aicardi-Goutières [16]. 
The frequency of some recently described genetic disorders (e.g., PRAAS2) cannot 
be counted [17]. Such disorders cause a great number of own nucleic acids in cell 
cytoplasm to appear. It results in active DNA recognition and pathological overex-
pression of type I IFN which launch autoimmunity hyperactivation, thus leading to 
autoimmune inflammation affecting the central and peripheral nervous system. It 
also results to skin and vessel damage (vasculitis), lung damage, etc. Therefore rapid 
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and efficient immune reaction to alien nucleic acids is positive when it causes type I 
IFN activation during pathogen invasion and antimicrobial protection. It becomes 
deleterious when it responds to own DNA which is due to the defect of own nucleic 
acid metabolism. Some neurological, vascular, and skin symptoms which are typical 
for type I interferonopathies are reviewed in such multifactorial diseases as exan-
thematous lupus erythematosus, widespread vasculitis, and autoimmune multiple 
myositis [6, 7, 18] (Table 2).
3.1.1  Target therapy by biologics in the treatment associated with type I IFN 
overexpression of type I IFN hyperproduction
Data available on genetic defects of intracellular nucleic acid metabolism greatly 
facilitate understanding of the mechanisms of insufficient immune activation, 
which can help in the development of new therapeutic approaches to the treatment 
of autoinflammatory and autoimmune diseases [1–3]. The progress in understand-
ing immunopathogenesis mechanism makes it possible to set the exact targets for 
new therapeutic strategy development [1, 2]. The immune dysregulation syndrome 
is characterized by a high level of IFNα, a deficiency of regulatory T-lymphocytes, 
impaired functioning of B cells, and low content of low-density neutrophils. These 
neutrophils easily form neutrophilic extracellular traps (NET), and the resulting 
DNA complexes provoke an increase in IFNα synthesis, and then pDC recognizes 
autoDNA and produces IFNα [10, 11, 19]. These disorders are observed primarily 
in systemic lupus erythematosus. New approaches in treatment of SLE and other 
type I interferonopathies have been developed. Monoclonal antibody therapy in 
type I interferonopathies treatment with SLE is sifalimumab, rontalizumab against 
IFNα, and anifrolumab against IFNα receptor (IFNAR). Baricitinib (JAK1/JAK2 
inhibitor) is currently at clinical studies (phases 2 and 3) in small cohort of patients 
with interferonopathies [20–22]. It is also known that treatment with baricitinib 
decreased disease signs and symptoms and allowed a significant reduction of 
corticosteroid treatment in patients with CANDLE and SAVI [23] (Figure 2).
3.2 Congenital interferonopathies associated with type I IFN deficiency
There are genetic defects in the synthesis of IFNα/IFNβ and IFNγ and defects in 
the receptors for IFNα and IFNγ (IFNAR and IFNGR) including genetic disorders 
associated with low IFN production according to recent studies. Those genetic 
I. Congenital interferonopathies II. Acquired—secondary 
interferonopathies
1. IFN deficiency
1.1 Interferon α deficiency (IFNα)
1.2 Interferon β deficiency (IFNβ)
1.3 Interferon γ deficiency (IFNγ)
2. Interferon overexpression
2.1 IFNα overexpression
2.1.1 Autoinflammatory syndromes and autoimmune diseases 
(systemic lupus erythematosus (SLE), systemic angiitis, 
dermatomyositis), Down syndrome
2.1.2 Type I interferonopathies: Aicardi-Goutières syndrome 
(AGS), familial chilblain lupus (FCL), spondyenchondromatosis, 






2. Interferon system paralysis
2.1 Blockage IFNα adequate response
2.2 Blockage IFNβ adequate response
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Syndrome Responsible gene Phenotypes
Aicardi-Goutières syndrome TREX1, RNASEH2B, 
RNASEH2C, RNASEH2A, 
SANHD, ADAR, IFIH1
Encephalopathy, muscular dystonia, 
microcephaly, calcification of the 
basal ganglia in the substance of 
the brain, cramps, fever, increased 
acute phase blood markers, 
cytopenia, increased levels of 




Cardiovascular diseases with 
aortic calcification, osteoporotic 
manifestations, dental and skeletal 
abnormalities, psoriatic skin lesions
Proteasome-associated 
autoinflammatory syndromes
Chronic atypical neutrophilic 
dermatosis with lipodystrophy







Erythematous skin lesions, 
panniculitis, lipodystrophy, 
arthritis with the development 
of joint contractures, myalgia, 
hepatomegaly, splenomegaly, 
calcification of the basal ganglia 
in the brain, fever, increased acute 
phase blood markers
Recurrent fevers in the first months 
of life, along with characteristic skin 
lesions, lipodystrophy, violaceous 
swollen eyelids, arthralgias, 
extremity contractures, and delayed 
physical development as well as 
systemic inflammation markers 
have been identified as CANDLE-
related clinical manifestations
STING-associated vasculopathy 
with onset in infancy (SAVI)
TMEM173 Vasculopathy with the formation 
of distal gangrene; necrosis; 
erythematous rash on the face, tip 
of the nose, and auricles; interstitial 
lung disease, arthralgia, fever
Spondyloenchondrodysplasia 
(SPENCD)
ACP5 Spondylometaphyseal dysplasia, 
stunting, calcification of the 
basal ganglia in the substance 
of the brain, arthropathy, 
thrombocytopenia, deficiency of 
cellular and humoral immunity
ISG15 deficiency ISG15 Calcification of the basal ganglia 
in the substance of the brain, 
convulsions, mycobacterial 
infections
USP18 deficiency (pseudo-TORCH 
syndrome)
USP18 Cerebral hemorrhage and 
calcification, hepatomegaly, 
thrombocytopenia
Trichohepatoenteric syndrome 2 SKIV2L Watery diarrhea, brittle and 
tangled hair, liver damage, mental 
retardation
Retinal vasculopathy with cerebral 
leukodystrophy (RVCL)
TREX1 The main characteristics of RVCL 
include the middle-age onset, the 
progressive visual loss due to retinal 
vasculopathy (telangiectasias, 
microaneurysms, and retinal 
capillary obliteration around the 
macula), and variable neurological 
manifestations such as dementia or 
migraine
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defects of IFNs are accompanied by clinical signs of severe recurrent viral and/or 
mycobacterial infection.
Congenital defects of type I IFN are associated with mutation of genes participat-
ing in synthesis of IFNα/IFNβ resulting to deficiency of various molecules (STAT1, 
UNC93B1, MCM4, TLR3, TRAF3, TRIF, TBK1) and decline level of IFNα/IFNβ. 
Deficiency of IFNγ, its receptor IFNGR (IFNγR1), and IL-12 plays an important 
role in IFNγ regulation [12, 24, 25]. Congenital defects of type I IFN have been glob-
ally systematized in 2015 by Bousfiha et al. [24]. It has been proven that it causes 
severe viral and bacterial intracellular infections which are the cause of deaths. Such 
patients are needed in replacement therapy with recombinant IFNα2b in complex 
Figure 2. 
Target therapies by biologics in the treatment of type I IFN overproduction. IFNAR, IFNα receptor; ISGs, 
interferon-stimulated genes; Tyk, tyrosine kinase; Jak, Janus kinase; pDC, plasmacytoid dendritic cell; STAT, 
signal transducer and activator of transcription.
Syndrome Responsible gene Phenotypes
Familial chilblain lupus TREX1 Rare monogenic form of cutaneous 
lupus erythematosus; partly 
ulcerating acral lesions or painful 
bluish-red papules located in 
the fingers, toes, nose, and ears; 
arthralgias, affecting mainly large 
joints, without evidence of true 
arthritis; photosensitivity; or mouth 
ulcers
X-linked reticulate pigmentary 
disorder (XLPDR)
POLA1 Generalized hyperpigmentation 
intermingled with small 
hypomelanotic macules during 
early childhood, a distinctive face 
characterized by an upswept frontal 
hairline and arched eyebrows, 
as well as severe photophobia, 
recurrent respiratory infections, 
and severe gastrointestinal disorders
Table 2. 
Genetic disorders associated with immune dysregulations and clinical characteristics of interferonopathies 
associated with type I IFN overexpression.
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with antioxidants. Congenital defects of IFNγR1 receptor are associated with severe 
intracellular mycobacterial infections. Combined genetic defects leading to deficiency 
of IFNα and IFNγ are associated with an autosomal recessive mutation in the STAT1 
gene, which causes severe viral and mycobacterial infections [12, 24, 25] (Table 3).
3.3 Acquired: secondary interferonopathies
There are secondary acquired disorders in the IFN system, which cause a 
weakening of antiviral resistance in adults and children [12]. Different viruses can 
damage synthesis and production of IFN at various interferonogenesis stages. These 
secondary defects of the type I IFN lead to the occurrence of severe viral infections 
Predominant susceptibility to viral infection
Syndrome Responsible gene Phenotypes











Dominant clinical phenotype is 
HSE during primary infection with 
HSV1, usually between 3 months 
and 6 years of age
Specific tests examining the TLR3 
pathway marked decrease on the 
ability of patient’s fibroblasts to 
produce IFNβ/IFNλ in response to 
TLR3 agonists and HSV1 infection
Warts, hypogammaglobulinemia, 
infection, myelokathexis (WHIM) 
syndrome
AD: CCXR4 Warts/human papilloma virus 
infection
Neutropenia, reduced B cell 
numbers
Epidermodysplasia verruciformis EVER1/TMC6, EVER2/
TMC8
Human papilloma virus (group B1) 




CD16 deficiency Severe viral infections
IRF7 deficiency Severe influenza disease
Susceptibility to mycobacteria
Syndrome Responsible gene Phenotypes
IRF8 deficiency AR: IRF8 Susceptibility to mycobacteria, 
Candida, myeloproliferation





Complete AR IFNGR1 and 
AR IFNGR2
Partial STAT1 LOF (AD), 
partial IFNGR1, partial 
IFNGR2, complete 
IL-12R1, complete IL-12B, 
complete ISG15, XL 
CYBB, IRF8, Tyk2, XL 
NEMO
Mycobacterial osteomyelitis
Serious disseminated BCG and 
environmental mycobacteria 
infections (soft tissue, bone 
marrow, lungs, skin, bones, and 
lymph nodes), Salmonella spp., 
Listeria monocytogenes, and viruses
Usually less severe
Table 3. 
Genetic disorders and clinical characteristics of interferonopathies associated with type I IFN deficiency.
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(herpesviral encephalitis), recurrent acute respiratory viral infections (recARVI), 
chronic recurrent HSV1 infection, atypical chronic EBV infections, and other atypi-
cal cases of virus infection. It was shown that viruses can avoid the effects of IFN 
and inhibit the action and synthesis of IFN using various molecular mechanisms. 
Numerous studies demonstrated that a lot of viruses (all herpesviruses, majority 
of respiratory viruses, hepatitis B and C viruses, etc.) produce proteins capable of 
inhibiting synthesis and production of IFNα/IFNβ and IFNγ. Viruses can damage 
each stage of the expression of ISGs [9] (Figure 3).
Patients with recurrent acute respiratory viral infections and various chronic her-
pesvirus infections including recurrent herpes viral infections have secondary defects 
of IFN system. Immunocompromised children of various ages and adults may suffer 
from recARVI with the frequency of 10 to 16–24 and more times annually; almost in 
100% of cases, it is associated with the presence of mono and mixed herpes viral infec-
tion. The frequency of recurrent chronic HSV1/HSV2 infection of facial and/or genital 
location in those patients may reach 16–24 times per year. Epstein-Barr virus may cause 
atypical virus infection associated with chronic fatigue syndrome [12].
3.3.1  Differentiated approaches to interferon therapy in patients with secondary 
interferonopathies
The problem of developing new approaches to the treatment of congenital and 
acquired defects of the IFN system is very acute [12, 26–28]. Acquired defects in the 
IFN system (93–96%) and impaired functioning of neutrophilic granulocytes (NG) 
are most often detected in patients with recurrent chronic herpes virus infections.
We conducted experiment in vitro to study the effect of recombinant IFNα2b 
(rIFNα2b) on NG in viral (cells from patients with HSV1/HSV2 infection) and 
bacterial (model infection by fMLP) infections. The study showed positive regula-
tion of the negatively charged IFNαβR1+IFNγR+TLR4+NG phenotype in patients 
with various chronic herpesvirus infections under the influence of rIFNα2b in vitro. 
Figure 3. 
Blockage of signaling pathways for the induction of interferon by viruses (red hexagons indicate the points 
of application of all herpesviruses, majority of respiratory viruses, chronic hepatitis B and C viruses, etc.). 
dsRNA, double-stranded RNA; IRF, IFN regulatory factor; IFNAR, IFNα receptor; ISGs, interferon-
stimulated genes; Tyk, tyrosine kinase; Jak, Janus kinase; NF-kB, nuclear factor kappa-light-chain-enhancer of 
activated B cells; cGAS, cyclic GMP-AMP synthase; MAVS, mitochondrial antiviral-signaling protein; MDA5, 
melanoma differentiation-associated protein 5; STAT, signal transducer and activator of transcription; TRIF, 
TIR domain-containing adaptor inducing interferon-beta; Ku70, component of the nonhomologous end-joining 
pathway that repairs DNA double-stranded breaks.
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It was noted that the number of NGs carrying IFNαβR1 and IFNγR and expression 
density of IFNαβR1 is increasing, wherein expression density of IFNγR and TLR4 
is decreased [29]. rIFNα2b modulating effects on CD16+CD66b+CD33+CD11b+NG 
phenotype transformed by fMLP in experimental model of bacterial process 
in vitro, to promote remodeling of the pro-inflammatory NG phenotype into anti-
inflammatory, have been shown [30]. Thus rIFNα2b has a protective effect on the 
NG phenotype according to experimental data.
In clinical practice, the use of parenteral IFN to correct disorders in the IFN 
system is very difficult due to the presence of numerous side effects. One should 
also bear in mind the inefficiency of short courses of IFN therapy for restoration 
of the normal IFN system functioning in recARVI, recurrent chronic herpes viral 
infection of facial or genital location, and papilloma virus infection of the skin and 
mucosa characterized by recurrent episodes when the frequency of recARVI and/
or recurrent attacks of HSV1/HSV2 infection may reach 14–24 and more per year. 
For over 20 years, we have been developing interferon therapy programs using 
drugs in Russian production—rectal suppositories and gel of recombinant human 
IFNα2b (rIFNα2b+aox) in combination with antioxidants (vitamins E and C) 
(Viferon) [12–15, 26, 27]. During that period, we managed to demonstrate safety, 
antiviral, and immunomodulatory efficiency of this kind of IFN therapy, total 
absence of any side effects that are typical for parenteral IFN therapy, and total 
absence of antibodies against IFNα2b. Replacement therapy with rIFNα2b + aox 
is prescribed to patients with primary, genetically preconditioned, congenital or 
acquired IFN system disorders. In case of primary IFN system disorders, patients 
need a basic recovery therapy making it possible to eliminate viral antigens as 
much as possible; and then it is required to select dosage for permanent replace-
ment therapy with rIFNα2b+aox. In case of acquired interferon deficiency, patients 
are prescribed with differentiated therapy with high, medium, and low doses of 
rIFNα2b+aox (Figure 4).
Figure 4. 
Dynamics of changes in the system of IFN in immunocompromised children against the background of therapy 
with rIFNα2b+aox (Viferon).
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At the same time, in case when we had treated the group of patients with 
combined immunodeficiency (defects of induced production of IFNα and IFNγ 
and dysfunctions of phagocytic and microbicidal activities of neutrophilic granu-
locytes) that was associated with recurrent acute respiratory viral infection and 
different chronic herpes viral coinfections, combined interferon and immunomod-
ulatory therapy was used. The aim was to restore the levels of induced production 
of IFNα and IFNγ and to reconstruct dysfunctions of phagocytic and microbicidal 
activities of neutrophilic granulocytes and other deficient chains in antiviral 
immunity. One group of children, group 1, received an interferon therapy program 
(rIFNα2b+aox), and patients in group 2 received a program of combined interferon 
therapy (rIFNα2b+aox) and immunotherapy (glucosaminylmuramyldipeptide). 
The use of replacement and immunomodulatory mono-rIFNα2b+aox or in com-
bination with immunotherapy (glucosaminylmuramyldipeptide) has helped us to 
receive very good clinical efficacies and has reached restoration of interferon status 
and normal functioning of neutrophilic granulocytes (p < 0.05) (Figure 5). At the 
same time, it is required to take into account both uneven viral infection syndrome 
manifestation and the rate of IFNα deficiency as well as peculiarities of immune 
system disorders in case of secondary immune deficiency [12–15, 27].
Here is an example illustrating the change in clinical, immune, and interferon 
status in immunocompromised children with recurrent acute respiratory viral 
infections under the influence of interferonotherapy.
Clinical case. Patient X, 3 years old. The child suffers from repeated acute 
respiratory viral infections 1–2 times per month (14–16 episodes per year); the 
duration of the acute period of respiratory viral infection is 7–10 days. The clinical 
symptoms of the disease were acute rhinitis, acute pharyngitis, acute laryngitis, 
acute tracheitis, febrile and subfebrile body temperature for 2–4 days, and severe 
symptoms of intoxication. The duration of the frequent incidence of acute respira-
tory viral infections is 2 years. The defects of the immune system are a decrease of 
CD3+CD4+ lymphocytes and CD3+CD8+ lymphocytes; a decrease of immunoregula-
tory index; neutropenia; a decrease of bacteria absorption and digestion processes 
by neutrophils; and a decrease of microbicidal activity of neutrophils. We tested 
spontaneous and Newcastle disease virus-induced IFN production during the 
incubation of peripheral blood (24 h, t 37°C in 5% CО2). The level of induced IFNα 
in the patient was 4 IU/ml versus 58 IU/ml in control. The patient was prescribed 
rIFNα2b+aox therapy with a total duration of 2.5 months.
Figure 5. 
The state of the interferon system in immunocompromised children with recurrent respiratory infections on the 
background of differentiated programs interferon and immunotherapy. Note: group 1 received an interferon 
therapy program (rIFNα2b+aox); group 2 received a program of combined interferon therapy (rIFNα2b+aox) 
and immunotherapy (glucosaminylmuramyldipeptide); (*p < 0.05, reliability in relation to control).
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Treatment program:
• Local intranasal use of rIFNα2b+aox (Viferon gel, 36,000 IU/g), two to three 
times a day, 6 weeks.
• Systemic rectal application of rIFNα2b+aox suppositories according to a  
“step-by-step” scheme:
300,000 IU per day, 10 days.
300,000 IU per day three times a week, 2 weeks.
300,000 IU per day two times a week, 2 weeks.
150,000 IU per day two times a week, 2 weeks.
150,000 IU per day once a week, 2 weeks.
Conducted local and systemic interferon therapy led to a reduction in the 
frequency of acute respiratory viral infections to three episodes per year lasting 
5–7 days, proceeding in a milder form. Rehabilitation of immunity parameters 
occurred after 2.5 months of interferonotherapy, and the level of induced IFNα was 
normalized to 64 IU/ml.
4. Conclusion
Summing up the above information, we may conclude that new biological drugs 
based on mAb are effective and safe, and they are able to neutralize IFNα overex-
pression in type I interferonopathies, both in Mendelian’s diseases and in autoim-
mune disorders. At the same time, local and system use of rIFNα2b+aox (Viferon) 
in congenital and acquired IFN system defects associated with viral infection 
syndrome, where a differential dosage is selected individually taking into account 
the rate of deficiency and an adequate, extended course of therapy is optimal 
because it is associated with positive clinical and immunological effects without any 
negative and side effects. Our more than 20-year experience has shown that using 
recIFNα2b+aox in patients with congenital or acquired IFN system defects had 
demonstrated positive clinical effect and is safe [31]. IFN (rIFNα2b+aox) therapy 
can be used with very good clinical efficacy in cases of primary or secondary defects 
of induced production of IFNα and IFNγ. From the other side, it is very important 
that in patients with a genetic predisposition to the manifestation of autoimmune 
diseases, primarily vasculitis and systemic lupus erythematosus, we do not recom-
mend to use IFN therapy.
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